Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $41.9 in the last session, down -1.94% from day before closing price of $42.73. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 0.77 million shares were traded. NKTR stock price reached its highest trading level at $42.61 during the session, while it also had its lowest trading level at $41.32.
Ratios:
We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 1.96 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on November 26, 2025, initiated with a Buy rating and assigned the stock a target price of $102.
On June 24, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $6.50 to $120.
BTIG Research reiterated its Buy rating for the stock on June 24, 2025, while the target price for the stock was revised from $60 to $100.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 25 ’25 when Zalevsky Jonathan sold 1,157 shares for $54.28 per share. The transaction valued at 62,802 led to the insider holds 18,971 shares of the business.
Wilson Mark Andrew sold 630 shares of NKTR for $34,196 on Nov 25 ’25. The Chief Legal Officer now owns 21,585 shares after completing the transaction at $54.28 per share. On Nov 25 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 2,207 shares for $54.28 each. As a result, the insider received 119,796 and left with 54,245 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 852312576 and an Enterprise Value of 749183552. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.62 while its Price-to-Book (P/B) ratio in mrq is 9.68. Its current Enterprise Value per Revenue stands at 11.968 whereas that against EBITDA is -5.542.
Stock Price History:
The Beta on a monthly basis for NKTR is -0.99, which has changed by 1.9673612 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $66.92, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is -24.94%, while the 200-Day Moving Average is calculated to be 33.36%.
Shares Statistics:
According to the various share statistics, NKTR traded on average about 841.74K shares per day over the past 3-months and 1336110 shares per day over the past 10 days. A total of 20.34M shares are outstanding, with a floating share count of 20.04M. Insiders hold about 1.48% of the company’s shares, while institutions hold 70.39% stake in the company. Shares short for NKTR as of 1765756800 were 1927352 with a Short Ratio of 2.29, compared to 1763078400 on 1813497. Therefore, it implies a Short% of Shares Outstanding of 1927352 and a Short% of Float of 9.6499994.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is -$2.59, with high estimates of -$2.59 and low estimates of -$2.59.
Analysts are recommending an EPS of between -$8.32 and -$8.32 for the fiscal current year, implying an average EPS of -$8.32. EPS for the following year is -$11.86, with 2.0 analysts recommending between -$11.6 and -$12.12.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $10.43M. It ranges from a high estimate of $15.81M to a low estimate of $6.9M. As of. The current estimate, Nektar Therapeutics’s year-ago sales were $29.18MFor the next quarter, 8 analysts are estimating revenue of $10.1M. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is $6M.
A total of 8 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $49.24M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $43.85M. In the same quarter a year ago, actual revenue was $98.43MBased on 8 analysts’ estimates, the company’s revenue will be $42.13M in the next fiscal year. The high estimate is $54.44M and the low estimate is $24M.
